

SUPERNUS PHARMACEUTICALS INC
Form SC 13D/A
March 26, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Amendment No.2)

Under the Securities Exchange Act of 1934

SUPERNUS PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, \$0.001 par value per share
(Title of Class of Securities)
868459108
(CUSIP Number)

John Heard

c/o Abingworth Management Limited

Princes House

38 Jermyn Street

London, England SW1Y 6DN

+44 20 7534 1500
(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

March 17, 2015
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. []

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 868459108

1. Names of Reporting Persons. I.R.S.
Identification Nos. of above persons (entities
only):

Abingworth
Management
Limited

2. Check the Appropriate
Box if a Member of a (a)
Group (See Instructions):
(b)

3. SEC Use Only
4. Source of Funds (See Instructions): WC
(See Item 3)

5. Check if Disclosure of Legal Proceedings
Is Required Pursuant to Items 2(d) or
2(e):

6. Citizenship or Place of
Organization: England

Number of	7. Sole	
	Voting	0
	Power:	
Shares	8. Shared	
Beneficially	Voting	2,405,066*
Owned by	Power:	
Each Reporting	9. Sole	
Person With	Dispositive	0
	Power:	
	10. Shared	
	Dispositive	2,405,066*
	Power:	

11. Aggregate Amount Beneficially Owned
by Each Reporting Person: 2,405,066*

12. Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See
Instructions):

13. Percent of Class Represented by
Amount in Row (11): 5.5%*

14. Type of Reporting Person (See Instructions): CO

* As of March 23, 2015, Abingworth Management Limited ("AML") may be deemed to beneficially own an aggregate of 2,405,066 shares of common stock, \$0.001 par value per share ("Common Stock"), of Supernus Pharmaceuticals, Inc. (the "Issuer"). The number of shares reported above consists of (i) 2,384,623 shares of Common Stock held by Abingworth Bioventures IV LP ("ABV IV") and (ii) 20,443 shares of Common Stock held by Abingworth Bioventures IV Executives LP ("ABV IV Execs," and together with ABV IV, the "Abingworth Funds"). AML, as the investment manager to the Abingworth Funds, may be deemed to beneficially own the 2,405,066 shares of Common Stock held by the Abingworth Funds.

Based on information disclosed by the Issuer in its annual report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 12, 2015, there were 44,089,023 shares of Common Stock issued and outstanding as of March 11, 2015. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, AML is deemed to beneficially own an aggregate of 2,405,066 shares of Common Stock, or 5.5% of the shares of Common Stock deemed issued and outstanding as of March 23, 2015

CUSIP No. 868459108

1. Names of Reporting Persons. I.R.S.

Identification Nos. of above persons (entities only):

Abingworth
Bioventures
IV LP

2. Check the Appropriate

Box if a Member of a (a)

Group (See Instructions):

(b)

3. SEC Use Only

4. Source of Funds (See Instructions): WC
(See Item 3)

5. Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items
2(d) or 2(e):

6. Citizenship or Place of
Organization: England

Number of	7. Sole	
	Voting	0
	Power:	
Shares	8. Shared	
Beneficially	Voting	2,384,623*
	Power:	
Owned by		
	9. Sole	
Each Reporting	Dispositive	0
	Power:	
	10. Shared	
Person With	Dispositive	2,384,623*
	Power:	

11. Aggregate Amount Beneficially Owned
by Each Reporting Person: 2,384,623*

12. Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See
Instructions):

13. Percent of Class Represented by
Amount in Row (11): 5.4%*

14. Type of Reporting Person (See
Instructions): PN

* As of March 23, 2015, ABV IV may be deemed to beneficially own an aggregate of 2,384,623 shares of Common Stock. Based on information disclosed by the Issuer in its annual report on Form 10-K filed with the SEC on March 12, 2015, there were 44,089,023 shares of Common Stock outstanding as of March 11, 2015. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, ABV IV is deemed to beneficially own an aggregate of 2,384,623 shares of Common Stock, or 5.4% of the shares of Common Stock deemed issued and outstanding as of March 23, 2015. AML, as the investment manager to ABV IV, may be deemed to beneficially own the 2,384,623 shares of Common Stock held by ABV IV.

CUSIP No. 868459108

1. Names of Reporting Persons. I.R.S.

Identification Nos. of above persons

(entities only):

Abingworth

Bioventures

IV

Executives

LP

2. Check the Appropriate (a)

Box if a Member of a []

Group (See Instructions):

(b) [X

]

3. SEC Use Only

4. Source of Funds (See

Instructions): WC (See Item 3)

5. Check if Disclosure of Legal

Proceedings Is Required Pursuant to

Items 2(d) or 2(e): []

6. Citizenship or Place of

Organization: Delaware

Number of 7. Sole
Voting 0
Power:

Shares 8. Shared
Beneficially Voting 20,443*
Power:

Owned by

Each 9. Sole
Reporting Dispositive 0
Power:

Person With 10. Shared
Dispositive 20,443*
Power:

11. Aggregate Amount Beneficially

Owned by Each Reporting

Person: 20,443*

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): []

13. Percent of Class Represented by Amount in Row (11): 0.1%*

14. Type of Reporting Person (See Instructions): PN

* As of March 23, 2015, ABV IV Execs may be deemed to beneficially own an aggregate of 20,443 shares of Common Stock. Based on information disclosed by the Issuer in its annual report on Form 10-K filed with the SEC on March 12, 2015, there were 44,089,023 shares of Common Stock outstanding as of March 11, 2015. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, ABV IV Execs is deemed to beneficially own an aggregate of 20,443 shares of Common Stock, or 0.1% of the shares of Common Stock deemed issued and outstanding as of March 23, 2015. AML, as the investment manager to ABV IV Execs, may be deemed to beneficially own the 20,443 shares of Common Stock held by ABV IV Execs.

Item 5. Interest in Securities of the Issuer

Item 5 is hereby amended and supplemented as follows:

(a) ABV IV is the owner of record of 2,384,623 shares of Common Stock. ABV IV may be deemed to beneficially own approximately 5.4% of the Issuer's outstanding Common Stock. The foregoing beneficial ownership percentage is based upon a total of 44,089,023 shares of Common Stock issued and outstanding as of March 11, 2015, as reported by the Issuer in its annual report on Form 10-K filed with the SEC on March 12, 2015.

ABV IV Execs is the owner of record of 20,443 shares of Common Stock. ABV IV Execs may be deemed to beneficially own approximately 0.1% of the Issuer's outstanding Common Stock. The foregoing beneficial ownership percentage is based upon a total of 44,089,023 shares of Common Stock issued and outstanding as of March 11, 2015, as reported by the Issuer in its annual report on Form 10-K filed with the SEC on March 12, 2015.

AML is not the owner of record of any shares of Common Stock. AML may be deemed to beneficially own, in the aggregate, 2,405,066 shares of Common Stock held by the Abingworth Funds, representing approximately 5.5% of the Issuer's outstanding Common Stock. The foregoing beneficial ownership percentage is based upon a total of 44,089,023 shares of Common Stock issued and outstanding as of March 11, 2015, as reported by the Issuer in its annual report on Form 10-K filed with the SEC on March 12, 2015.

(b) As set forth in the cover sheets to this Amendment No. 2 to Schedule 13D, (i) ABV IV has shared voting and dispositive power with respect to the 2,384,623 shares of Common Stock held by ABV IV and has sole voting and dispositive power over none of the securities reported herein; (ii) ABV IV Execs has shared voting and dispositive power with respect to the 20,443 shares of Common Stock held by ABV IV Execs and has sole voting and dispositive power over none of the securities reported herein; and (iii) AML has shared voting and dispositive power with respect to the 2,405,066 shares of Common Stock held by the Abingworth Funds and has sole voting and dispositive power over none of the securities reported herein.

(c) The following table details the transactions by the Reporting Persons, on behalf of the Abingworth Funds, in Common Stock during the period commencing sixty (60) days prior to March 23, 2015:

Date	Price per Share	Type of Transaction	Number of Shares
3/17/15	\$11.1252 ⁽¹⁾	Open Market Sale	82,900
3/18/15	\$11.176 ⁽²⁾	Open Market Sale	61,050
3/18/15	\$11.267 ⁽³⁾	Open Market Sale	28,174
3/19/15	\$11.3153 ⁽⁴⁾	Open Market Sale	115,776
3/19/15	\$11.4225 ⁽⁵⁾	Open Market Sale	143,950
3/20/15	\$11.5103 ⁽⁶⁾	Open Market Sale	9,609
3/23/15	\$11.5035 ⁽⁷⁾	Open Market Sale	32,803

Explanation of response:

1. The price reported in Item 5(c) is a weighted average price. These shares were bought in multiple transactions at prices ranging from \$11.10 to \$11.34, inclusive. The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

2. The price reported in Item 5(c) is a weighted average price. These shares were bought in multiple transactions at prices ranging from \$11.10 to \$11.31, inclusive. The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

3. The price reported in Item 5(c) is a weighted average price. These shares were bought in multiple transactions at prices ranging from \$11.25 to \$11.36, inclusive. The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

4. The price reported in Item 5(c) is a weighted average price. These shares were bought in multiple transactions at prices ranging from \$11.25 to \$11.49, inclusive. The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

5. The price reported in Item 5(c) is a weighted average price. These shares were bought in multiple transactions at prices ranging from \$11.35 to \$11.65, inclusive. The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares bought at each separate price within the range set forth

in this footnote.

6. The price reported in Item 5(c) is a weighted average price. These shares were bought in multiple transactions at prices ranging from \$11.50 to \$11.59, inclusive. The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

7. The price reported in Item 5(c) is a weighted average price. These shares were bought in multiple transactions at prices ranging from \$11.50 to \$11.53, inclusive. The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

Except as set forth in this Schedule 13D, none of the persons identified in Item 2 of this Schedule 13D has engaged in any transaction in Shares, or securities convertible for Shares, during the period commencing sixty (60) days prior to March 23, 2015.

(d) Each Abingworth Fund has the right to receive dividends from, or proceeds from the sale of, the shares of Common Stock beneficially owned by it. The limited partners or shareholders of each Abingworth Fund have the right to participate indirectly in the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock beneficially owned by it, in accordance with their respective ownership interests in such Abingworth Fund.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 25, 2015

**Abingworth BIOVENTURES
iv, lp**

By: Abingworth Management
Limited, its Manager

By: /s/ John Heard
Name: John Heard
Title: Authorized Signatory

**Abingworth Bioventures IV
Executives LP**

By: Abingworth Management
Limited, its Manager

By: /s/ John Heard
Name: John Heard
Title: Authorized Signatory

**Abingworth Management
Limited**

By: /s/ John Heard
Name: John Heard
Title: Authorized Signatory

**Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).**